为您找到相关结果约170个

你是不是要搜索 期刊Alisertib 点击跳转

Correlates of alisertib response

Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent

A PhaseIITrial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Paclitaxel and Alisertib in Recurrent Ovarian Cancer

Paclitaxel and Alisertib in Recurrent Ovarian Cancer Reply

Combining selinexor with alisertib to target the p53 pathway in neuroblastoma

Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing

Alisertib: a new option for acute myeloid leukaemia

COMPLETE RESPONSE OF THERAPY RELATED MYELODYSPLASTIC SYNDROME TO ALISERTIB

Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic

Alisertib exerts KRAS allele-specific anticancer effects on colorectal cancer cell lines

Target Identification of Kinase Inhibitor Alisertib (MLN8237) by Using DNA-Programmed Affinity Labeling

Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies

Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib

Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents

为您找到相关结果约170个

共170条页码: 1/12页15条/页